Compare Stocks → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:EYEGOTCMKTS:IGXTNASDAQ:INNTNASDAQ:OHRP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$6.63-4.3%$5.01$1.01▼$7.12$32.42M2.1938,826 shs22,865 shsEYEGAB Corporate Bond ETF$35.75+0.1%$1.90$1.44▼$8.18$451.12M0.81935,975 shsN/AIGXTIntelGenx Technologies$0.18-4.3%$0.16$0.09▼$0.26$30.74M2.4290,580 shs46,392 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs40 shsOHRPOHR Pharmaceutical$0.43-8.4%$7.37$1.60▼$6.28$1.23M0.84180,228 shs656,232 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics+22.66%+28.91%+51.50%+122.96%+445.38%EYEGAB Corporate Bond ETF+0.43%+0.71%+1.31%-0.98%+1,732.20%IGXTIntelGenx Technologies+6.98%+18.25%+26.72%+40.46%+4.10%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.92%OHRPOHR Pharmaceutical-9.21%-59.37%-52.89%-38.86%+149.83%the most reliable asset on earth is making a comeback (Ad)Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click HereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics3.4841 of 5 stars3.55.00.00.03.91.70.6EYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$9.0035.75% UpsideEYEGAB Corporate Bond ETFN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$4.10 per shareN/AEYEGAB Corporate Bond ETF$10K45,112.29N/AN/A$1.26 per share28.37IGXTIntelGenx Technologies$1.04M29.56N/AN/A($0.07) per share-2.51INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AOHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$27.33MN/A0.00N/AN/AN/A-83.80%-72.25%4/1/2024 (Estimated)EYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-955.44%N/A-128.18%N/AINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AOHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/ALatest ALRN, EYEG, IGXT, INNT, and OHRP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IGXTIntelGenx TechnologiesN/A-$0.02-$0.02-$0.03N/A$0.43 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/ALatest ALRN, EYEG, IGXT, INNT, and OHRP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A7.887.88EYEGAB Corporate Bond ETF0.013.073.07IGXTIntelGenx TechnologiesN/A0.410.40INNTInnovate BiopharmaceuticalsN/A0.350.35OHRPOHR PharmaceuticalN/A3.733.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%EYEGAB Corporate Bond ETF64.16%IGXTIntelGenx TechnologiesN/AINNTInnovate Biopharmaceuticals5.88%OHRPOHR Pharmaceutical10.70%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%EYEGAB Corporate Bond ETF58.20%IGXTIntelGenx Technologies42.05%INNTInnovate Biopharmaceuticals7.90%OHRPOHR Pharmaceutical12.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics64.89 million4.61 millionNot OptionableEYEGAB Corporate Bond ETF1412.62 million5.28 millionNot OptionableIGXTIntelGenx Technologies4174.66 million101.21 millionNot OptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableALRN, EYEG, IGXT, INNT, and OHRP HeadlinesSourceHeadlineCYCC Cyclacel Pharmaceuticals, Inc.seekingalpha.com - March 17 at 4:20 PMSun Pharmaceutical Industries Ltd.moneycontrol.com - February 3 at 8:52 AMAI Advances Pharmaceutical Packaging Inspectiondesignnews.com - May 22 at 9:22 AMThe OHRP and SUPPORT — Another Viewnejm.org - April 21 at 3:16 PMWorking at the Smithsoniansi.edu - February 23 at 5:49 PMOHR Pharmaceutical (OHRP) is now in Oversold Territoryca.finance.yahoo.com - September 12 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.IntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.